NCT07308717 Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
| NCT ID | NCT07308717 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,896 participants |
| Start Date | 2025-12-16 |
| Primary Completion | 2027-12-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 1,896 participants in total. It began in 2025-12-16 with a primary completion date of 2027-12-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess whether gabapentin should be a standard component of peri-operative pain control in mastectomy patients at Memorial Sloan Kettering Cancer Center.
Eligibility Criteria
Inclusion Criteria: * Age 18 to 65 years * Undergoing ambulatory extended recover (AXR) mastectomy (bilateral or unilateral) at the Josie Robertson Surgical Center (JSRC) Exclusion Criteria: * None
Contact & Investigator
James Flory, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07308717 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07308717 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07308717 currently recruiting?
Yes, NCT07308717 is actively recruiting participants. Contact the research team at floryj@mskcc.org for enrollment information.
Where is the NCT07308717 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07308717 clinical trial?
NCT07308717 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is James Flory, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 1,896 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.